Erorr
Erorr
Erorr

Pasbion News

Erorr

Urovant poaches Allergan's key urology executive Cornelia Haag-Molkenteller

Urovant Sciences is bringing on Allergan’s Cornelia Haag-Molkenteller as its chief medical officer and establishing a new U.S. headquarters in California. The move comes shortly after launching a phase 3 trial for vibegron, its sole drug candidate, in overactive bladder.

Read More

Shire-hunting Takeda notches R&D collaboration with Nektar, pair to combo I-O drugs

Takeda, with apparently near infinitely deep pockets for M&A and collaborations, has struck a deal: not to buy Shire, as yet, but rather with Nektar, as the two eye new trials of their respective immuno-oncology assets.

Read More

FDA slaps partial hold on Epizyme’s lead drug; analysts say ‘don’t panic’

Shares in Epizyme slipped in premarket trading today after the company announced a suspension of patient recruitment in a trial of its lead cancer drug after a patient developed a secondary lymphoma, but analysts at Jefferies are expecting the stock to bounce back.

Read More

Alnylam builds out case for patisiran, showing sharp drop in hospitalization, mortality

Alnylam has presented a fresh take on its phase 3 patisiran data as it builds out its case ahead of an anticipated landmark approval. The new angle comes from an exploratory post hoc analysis which linked the RNAi therapy to a 50% drop in all-cause hospitalization and mortality over placebo.

Read More

Eli Lilly unveils galcanezumab migraine analysis as FDA decisions near

Eli Lilly presented a post hoc analysis of its monthly migraine therapy galcanezumab, one of a new class of targeted preventive drugs, as it looks to show the drug's effectiveness after the failure of other treatments.

Read More

Restless R&D executives, and a few FDA staffers, on the move to rival pharmas

There are only so many things you can do as a pharma R&D executive when you start to get a little grim about the mouth, or whenever you feel a drizzly November in your soul: you go to sea, jumping ship into young biotechs, or sail out into the new world of venture capitalism.

Read More

Sanofi hires ex-Roche executive John Reed to replace retiring Elias Zerhouni as R&D chief

Sanofi is changing its head of global R&D. Elias Zerhouni, M.D., is to retire from the position at the end of June, leaving former Roche research leader John Reed, M.D., Ph.D., to take charge of Sanofi’s pipeline.

Read More

FDA still not happy with Kamada inhaled AAT drug

Israeli biotech Kamada has hit another hurdle in its marathon bid to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency to market as an alternative to intravenous drugs.

Read More

Synthetic Biologics loses breakthrough status after FDA discovers death imbalance in trial data

Synthetic Biologics has lost its breakthrough designation for ribaxamase following a review of the data by the FDA. The review revealed an imbalance in patient deaths in a phase 2b trial of the drug, leading the FDA to conclude ribaxamase no longer meets the requirements for its breakthrough status.

Read More

Targeting heart disease by focusing on a protein that dilates blood vessels

Scientists at Scripps Research Institute have pinpointed a protein that can sense blood flow and prompt tiny blood vessels called arterioles to dilate. They believe the protein, called GPR68, could be a valuable target for drug development.

Read More

After Kerrisdale predictions of failure, Prothena dumps AL amyloidosis drug

Prothena missed primary and secondary endpoints in its key AL amyloidosis drug NEOD001 in a midstage test, with predictions it also wouldn’t cut it in phase 3, leading the company to dump work on the therapy.

Read More

Sanofi diabetes research chief takes CSO post at Grünenthal

Sanofi is set to lose its global head of diabetes research and translational medicine to Grünenthal. Philip Just Larsen, M.D., Ph.D., will join the German pain specialist at the start of July, leaving Sanofi looking for a diabetes research chief and CSO for its Frankfurt hub.

Read More

A compound from immune cells could treat psoriasis, other autoimmune diseases

Itaconate, a compound produced by inflammatory cells, relieved psoriasis-like symptoms in mice. It could have uses beyond psoriasis as it targets the IL-17 pathway, which is implicated in many autoimmune diseases.

Read More

Gene editing shows promise in combating HIV reservoirs

Gene therapy has experienced a renaissance of late, and it’s a technology that many researchers in HIV are embracing. That's because the ability to manipulate genes—particularly CCR5, which is known to play a role in HIV resistance—could help eliminate dormant reservoirs of virus that can resurge at any time.

Read More

UCB offers $370M for Proximagen’s epilepsy spray, with NDA to follow

UCB plans to bolster its epilepsy portfolio by acquiring a nasal spray developed by Proximagen, agreeing to pay $150 million up front, with biobucks of $220 million also in the cards.

Read More

Biogen pays Ionis $1B to form discovery-stage pact

Biogen is paying $1 billion to enter into a discovery-stage R&D pact with Ionis Pharmaceuticals. The deal gives Biogen a chance to pick up a series of neurological antisense drugs identified by Ionis.

Read More

FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety.

Read More

MorphoSys supersizes IPO, bagging $208M for cancer R&D

MorphoSys has supersized its IPO, pulling in $208 million to develop its anti-CD19 antibody MOR208. The dialed-up IPO haul gives MorphoSys a $500 million-plus war chest to crash the CAR-T party with a drug it thinks provides safer, more durable efficacy without the cost or complexity of cell therapies.

Read More

After questioning Lilly/Incyte's baricitinib, FDA director jumps ship to AstraZeneca

The FDA’s Badrul Chowdhury is moving to AstraZeneca in the same week that he made a series of critical marks against Eli Lilly and Incyte's long-delayed baricitinib, which is set for an advisory committee on Monday.

Read More

Grail to seek an additional $1B in funding before Hong Kong IPO, report says

Cancer blood test developer Grail is reportedly considering whether to squeeze in yet another billion-dollar funding round before it goes public in Hong Kong later this year, according to Bloomberg.

Read More

CNS Pharma turns to crowdfunding to advance glioblastoma drug

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor if phase 2 trials are positive.

Read More

Tmunity dials series A round up to $135M to fuel progress of T-cell immunotherapy pipeline

Tmunity has added $35 million to its series A round, bringing its total haul up to $135 million. The cash sets ex-Novartis executive Usman “Oz” Azam up to build out the infrastructure Tmunity needs to hustle its pipeline of T cell-based immunotherapies through clinical development.

Read More

Novartis lures John Tsai from Amgen to fill CMO seat

Vas Narasimhan, M.D., has persuaded John Tsai, M.D., to fill the vacant CMO role at Novartis. Tsai took up the same position at Amgen just 11 months ago but had his head turned by the digitally enabled pipeline Narasimhan is building at Novartis.

Read More

Novartis’ Jay Bradner bemoans 'redundant investment in the biotech sector' for some cancer R&D

Jay Bradner, president of Novartis’ Institutes for BioMedical Research, questions whether billions in cancer research funding is going in the right direction as he points out a “flood of fast followers, narrow differentiators and distracting hype” around some new therapies and research.

Read More

'Cell-free' CRISPR could improve cancer diagnostics, unravel how gene editing works

Christiana Care scientists edited DNA outside the cell for what they say is the first time, laying the groundwork for a diagnostic test that can replicate DNA mutations in a patient's tumor and help physicians identify the more appropriate treatment.

Read More

Contact Us

PASBION HEALTHCARE INC
1747 S. Douglass Road, Suite C
Anaheim, California 92806
714.231.9876

PASBION HEALTHCARE INC
Building No X111/2a. M.C Road,
Kalady-683 574,Ernakulam Dist,
Kerala, India
+91 -8606 44 88 90
info@pasbion.com

Contact Us

Erorr

PASBION HEALTHCARE INC

1747 S. Douglass Road, Suite C

Anaheim, California 92806

714.231.9876